5-acetyl-1-methyl-1H-benzo[d]imidazol-2(3H)-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 5-acetyl-1-methyl-1H-benzo[d]imidazol-2(3H)-one
• 英文别名: 6-acetyl-3-methyl-1H-benzimidazol-2-one
• 化学式: C₁₀H₁₀N₂O₂
• 分子量: 190.202
• InChiKey: JGNFANGTKXOIME-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  49.4
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-acetyl-1-methyl-1H-benzo[d]imidazol-2(3H)-one 在 copper(ll) bromide 作用下， 以 乙醇 、 二氯甲烷 、 乙酸乙酯 为溶剂， 反应 16.0h， 以32%的产率得到5-(2-bromoacetyl)-1-methyl-1H-benzo[d]imidazol-2(3H)-one
  参考文献：
  名称：

  [EN] KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE
  [FR] COMPOSÉS INHIBITEURS DE KINASE, COMPOSITIONS ET PROCÉDÉS D'UTILISATION

  摘要：

  本发明涉及具有以下结构的激酶抑制剂化合物：或其立体异构体、药用盐、氧化物或溶剂合物，其中R1、R2、X、n、R3、Y、Z、R4、R5、R6和=如本文所定义。本发明还涉及含有激酶抑制剂化合物的组合物，抑制细胞中激酶活性的方法，增加胰岛β细胞群体中细胞增殖的方法，治疗由于胰岛素分泌不足引起的病症的方法，以及治疗神经疾病的方法。

  公开号：

  WO2019100062A1
• 作为产物：
  描述：

  3-氨基-4-(甲基氨基)苯羧酸甲酯 在 lithium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 48.0h， 生成 5-acetyl-1-methyl-1H-benzo[d]imidazol-2(3H)-one
  参考文献：
  名称：

  [EN] KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE
  [FR] COMPOSÉS INHIBITEURS DE KINASE, COMPOSITIONS ET PROCÉDÉS D'UTILISATION

  摘要：

  本发明涉及具有以下结构的激酶抑制剂化合物：或其立体异构体、药用盐、氧化物或溶剂合物，其中R1、R2、X、n、R3、Y、Z、R4、R5、R6和=如本文所定义。本发明还涉及含有激酶抑制剂化合物的组合物，抑制细胞中激酶活性的方法，增加胰岛β细胞群体中细胞增殖的方法，治疗由于胰岛素分泌不足引起的病症的方法，以及治疗神经疾病的方法。

  公开号：

  WO2019100062A1

文献信息

• KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE
  申请人：ICHAN SCHOOL OF MEDICINE AT MOUNT SINAI

  公开号：US20200306257A1

  公开（公告）日：2020-10-01

  The present invention is directed to kinase inhibitor compounds having the following structure: or a stereoisomer, pharmaceutically acceptable salt, oxide, or solvate thereof, where R 1 , R 2 , X, n, R 3 , Y, Z, R 4 , R 5 , R 6 , and = are as defined herein. The present invention also relates to compositions containing the kinase inhibitor compounds, methods of inhibiting activity of a kinase in a cell, methods of increasing cell proliferation in a population of pancreatic beta cells, methods of treating a subject for a condition associated with insufficient insulin secretion, and methods of treating a subject for a neurological disorder.
• METHOD OF INCREASING PROLIFERATION OF PANCREATIC BETA CELLS, TREATMENT METHOD, AND COMPOSITION
  申请人：ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI

  公开号：US20210032601A1

  公开（公告）日：2021-02-04

  Disclosed herein are methods of increasing cell proliferation in a population of pancreatic beta cells. Also disclosed are methods of treating a subject for a condition associated with insufficient insulin secretion. Also disclosed is a composition comprising a DYRK1 A inhibitor and a GLP1R agonist. The disclosure further describes a method of regenerating pancreatic beta cells in a transplant patient.
• [EN] METHOD OF INCREASING PROLIFERATION OF PANCREATIC BETA CELLS, TREATMENT METHOD, AND COMPOSITION<br/>[FR] PROCÉDÉ D'AUGMENTATION DE LA PROLIFÉRATION DE CELLULES BÊTA PANCRÉATIQUES, PROCÉDÉ DE TRAITEMENT ET COMPOSITION
  申请人：ICAHN SCHOOL MED MOUNT SINAI

  公开号：WO2019136320A1

  公开（公告）日：2019-07-11

  Disclosed herein are methods of increasing cell proliferation in a population of pancreatic beta cells. Also disclosed are methods of treating a subject for a condition associated with insufficient insulin secretion. Also disclosed is a composition comprising a DYRK1 A inhibitor and a GLP1R agonist. The disclosure further describes a method of regenerating pancreatic beta cells in a transplant patient.
• [EN] KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE<br/>[FR] COMPOSÉS INHIBITEURS DE KINASE, COMPOSITIONS ET PROCÉDÉS D'UTILISATION
  申请人：ICHAN SCHOOL OF MEDICINE AT MOUNT SINAI

  公开号：WO2019100062A1

  公开（公告）日：2019-05-23

  The present invention is directed to kinase inhibitor compounds having the following structure: or a stereoisomer, pharmaceuticallyacceptable salt, oxide, or solvate thereof, where R1, R2, X, n, R3, Y, Z, R4, R5, R6, and = are as defined herein. The present invention also relates to compositions containing the kinase inhibitor compounds, methods of inhibiting activity of a kinase in a cell, methods of increasing cell proliferation in a population of pancreatic beta cells, methods of treating a subject for a condition associated with insufficient insulin secretion, and methods of treating a subject for a neurological disorder.

  本发明涉及具有以下结构的激酶抑制剂化合物：或其立体异构体、药用盐、氧化物或溶剂合物，其中R1、R2、X、n、R3、Y、Z、R4、R5、R6和=如本文所定义。本发明还涉及含有激酶抑制剂化合物的组合物，抑制细胞中激酶活性的方法，增加胰岛β细胞群体中细胞增殖的方法，治疗由于胰岛素分泌不足引起的病症的方法，以及治疗神经疾病的方法。